SENSEX NIFTY
Jun 12, 2007, 06.34 PM IST | Source: CNBC-TV18

Will scale up bio-informatics services: Celestial Labs

Aditya Narayan Singh, CFO, Celestial Labs, said the company is going to scale up its services in the bio-informatics area. He added the company is also planning to set up a facility for producing industrial enzymes.

Aditya Narayan Singh, CFO, Celestial Labs
Aditya Narayan Singh , CFO , Celestial Labs , said the company is going to scale up its services in the bio-informatics area. He added the company is also planning to set up a facility for producing industrial enzyme s.

The company is also planning to launch a product - Cell Suite .

Excerpts from CNBC-TV18s exclusive interview with Aditya Narayan Singh:

Q1: Can you take us through the main business lines of the company and what are your plans to do with the money that you raise?

A: We are basically working in the bio-informatics area and would like to scale up our services in that area. We also wanted to set up a facility for producing industrial enzymes and take up drug molecule development, which is in the existing line of business.

Q2: Give us more details about your business, what sort of EPS and balance sheet did you clock the previous quarter?

A: Last year, we did a Rs 14 crore turnover and the profit after tax was at Rs 5.25 crore. We have an EPS of Rs 8.25.

Q3: We understand that you are going to be licensing a product called Cell Suite. Can you take us through when you are expecting this licensing?

A: We have started that process. In fact, we are first using Cell Suite ourselves to create the drug molecule. We are in the process of licensing Cell Suite in the next two to three months.

Q4: And, what kind of revenue upsides can that product bring to you?

A: Cell Suite has been priced at USD 18,000 per user license, which is against the price of about one-third of the cost of the imported tool.

ADS BY GOOGLE

video of the day

Market to correct if no reforms; like Dabur, Marico: Kotak

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.